PCM
MRNA icon

Pennsylvania Capital Management’s Moderna MRNA Stock Holding History

Pennsylvania Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-18,881
Closed -$1.21M – 103
2020
Q2 		$1.21M Buy
+18,881
New +$1.03M 0.65% 34

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Pennsylvania Capital Management's MRNA Position: Q3 2020 in Review

Pennsylvania Capital Management sold out of Moderna (MRNA) in Q3 2020, closing a stake of 18,881 shares — an estimated $1.21M sold.

Pennsylvania Capital Management first reported a position in MRNA in Q2 2020 and held it in 1 quarter. The position peaked at $1.21M in Q2 2020. 547 funds tracked by Wall St. Rank hold MRNA as of Q3 2020.

  • Pennsylvania Capital Management reported no remaining Moderna position as of Q3 2020 after selling out during the quarter.
  • Pennsylvania Capital Management sold 18,881 Moderna shares in Q3 2020, an estimated $1.21M.
  • Pennsylvania Capital Management first reported a position in Moderna in Q2 2020 and held it in 1 quarter.
  • Pennsylvania Capital Management's Moderna position peaked at $1.21M in Q2 2020.
  • 547 funds tracked by Wall St. Rank held Moderna as of Q3 2020.

Based on Pennsylvania Capital Management's 13F filing for Q3 2020, filed 7 Oct 2020.